Results 191 to 200 of about 149,933 (301)

Self-reported late effects and chronic fatigue, information needs and follow-up in long-term survivors of Hodgkin lymphoma-a cross-sectional study. [PDF]

Support Care Cancer
Willumsen LH, Smeland KB, Eikeland S, Fosså A, Bersvendsen HS, Fagerli UM, Falk RS, Lie HC, Skaali T, Kiserud CE.   +9 more
europepmc   +1 more source

Circulating miR-148a-3p Correlates with Inadequate Induction Response in Pediatric Hodgkin Lymphoma. [PDF]

Immunotargets Ther
Rohde M, Singh VK, Wolfermann A, Burkhardt B, Blattmann C, Steinbach D, Schneider DT, Ebinger M, Maecker-Kolhoff B, Braun M, Kurch L, Mauz-Körholz C, Körholz D.   +12 more
europepmc   +1 more source

Brentuximab vedotin with chemotherapy for stage III or IV Hodgkin\u27s lymphoma [PDF]

, 2018
Bartlett, N. L, et al,
core   +1 more source

Emerging Techniques in Minimally Invasive Surgery in Hematologic Malignancies

European Journal of Haematology, EarlyView.
ABSTRACT Hematologic malignancies represent the most common cancers in children. While the mainstays of treatment are chemotherapy and potentially hematopoietic stem cell transplant, minimally invasive surgery (MIS) has a role in the diagnosis and management of complications related both to disease and therapy as well as common pediatric surgical ...
Alejandro Chara, Katlyn G. McKay, Harold N. Lovvorn III, Joseph C. Fusco   +3 more
wiley   +1 more source

Treatment Outcomes of Advanced Stage Classical Hodgkin Lymphoma in the Setting of Vinblastine and Dacarbazine Shortages: A Case Series. [PDF]

Case Rep Oncol Med
Satyavarapu I, Giese N, Gandhi P, Umoru G, Burns EA, Pingali SR.   +5 more
europepmc   +1 more source

Loncastuximab Tesirine in Relapsed/Refractory Diffuse Large B‐Cell Lymphoma: Evidence and Practical Guidance From Italian Clinical Experience

European Journal of Haematology, EarlyView.
ABSTRACT Patients with relapsed/refractory (R/R) diffuse large B‐cell lymphoma (DLBCL) who progress to the third‐line setting face a lack of standardized treatment, despite the presence of multiple available therapies. In this context, antibody–drug conjugates represent a relatively new class of anticancer agents; among them, loncastuximab tesirine is ...
Francesca Bonello, Andrea Aroldi, Alessia Castellino, Lara Mannelli, Elia Boccellato, Serena Rosati, Luisa Verga, Umberto Vitolo   +7 more
wiley   +1 more source

Bibliometric analysis of global hodgkin lymphoma research from 2002 to 2022. [PDF]

Discov Oncol
Okoroiwu HU, Povedano-Montero FJ, Asanga EE, Etura JE, Okoroiwu EN, Igwe KN, Edet UO, Atim-Ebim MR, Ogar CO, Umoh EA, Uzor SO, Emmanuel KJ, Uchendu IK, Oreh A, Nwaiwu NP, Bisong EO, Dozie-Nwakile OC, Echieh CP, Abunimye DA, Asemota EA, Okafor IM, Mittal P, Ogar VO, Igbinovia MO, Aniokete UC, Odaghara CJV, Ude UT, Oluwaseyi OA, Finbarrs-Bello E, Nwadum EF, Okekpa SI, Udujih HI, Onyema AS, Oshim IO, Okereke JI, Ekup EU, Ugwu JI, Obasi E, López-Muñoz F.   +38 more
europepmc   +1 more source

Low Risk of Central Nervous System Relapse Among Patients With T‐Cell/Histiocyte‐Rich Large B‐Cell Lymphoma Despite High‐Risk Disease Presentation

European Journal of Haematology, EarlyView.
ABSTRACT T‐cell/histiocyte‐rich large B‐cell lymphoma (THRLBCL) is a rare subtype of large B‐cell lymphoma (LBCL) for which central nervous system (CNS) relapse remains a devastating complication. The CNS International Prognostic Index (IPI) is usually used to predict the risk of CNS relapse. However, the overall risk of CNS relapse among patients with
Atte Karhu, Sara Aronen, Aino Rönkä, Kaisa Sunela, Tuula Klaavuniemi, Annikki Aromaa‐Häyhä, Milla Kuusisto, Otto Jokelainen, Jan Böhm, Kristiina Vuolukka, Ulla‐Mari Arkko, Samuli Vaittinen, Minna Harmanen, Juha P. Väyrynen, Hanne Kuitunen, Sonja Nousiainen, Joonas Kuitunen, Juho Kangas, Eetu Pellonperä, Henri Kurttila, Miko Pietilä, Jaakko Tirkkonen, Outi Kuittinen   +22 more
wiley   +1 more source

Promising outcomes of R-CHOP therapy in pediatric nodular lymphocyte-predominant Hodgkin lymphoma: perspectives from a rare subtype. [PDF]

Front Oncol
Ali N, Khorshed E, Zaghloul MS, Mehsen M, Badawy S, Elsayed W.   +5 more
europepmc   +1 more source

Real‐world comparison of peripheral neuropathy and treatment delivery between Pola‐R‐CHP and R‐CHOP in DLBCL

British Journal of Haematology, EarlyView.
Nobuhiko Nakamura, Koichi Ohata, Tomohiro Aizaki, Yuto Kaneda, Yoshikazu Ikoma, Takuro Matsumoto, Hiroshi Nakamura, Serika Banno Matsuoka, Shiori Hishida Sadaka, Akio Suzuki, Nobuhiro Kanemura, Masahito Shimizu   +11 more
wiley   +1 more source